Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma

被引：23
作者：
Bhatt, R. S. [1 ]
Zurita, A. J. [2 ]
O'Neill, A. [3 ]
Norden-Zfoni, A. [4 ,5 ]
Zhang, L. [1 ]
Wu, H. K. [4 ,5 ]
Wen, P. Y. [6 ]
George, D. [7 ]
Sukhatme, V. P. [8 ]
Atkins, M. B. [1 ]
Heymach, J. V. [4 ,5 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Div Hematol Oncol & Canc Biol, Boston, MA 02215 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Harvard Univ, Sch Med, Childrens Hosp, Dept Biostat & Computat Biol,Dana Farber Canc Ins, Boston, MA 02215 USA
[4] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Canc Biol, Houston, TX 77030 USA
[6] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02115 USA
[7] Duke Univ, Med Ctr, Div Med Oncol & Urol, Durham, NC 27705 USA
[8] Beth Israel Deaconess Med Ctr, Dept Med, Div Interdisciplinary Med & Biotechnol, Boston, MA 02215 USA
来源：
BRITISH JOURNAL OF CANCER | 2011年 / 105卷 / 01期
基金：
美国国家卫生研究院;
关键词：
circulating endothelial cells; von Hippel-Lindau (VHL) disease; renal cancer; biomarker; angiogenesis; SURROGATE MARKER; THERAPY; CANCER; BIOMARKERS; INHIBITOR; BLOOD;
D O I：
10.1038/bjc.2011.186
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BACKGROUND: Circulating endothelial cells (CECs) are a candidate biomarker for monitoring angiogenesis in cancer. Circulating endothelial cell subsets are mobilised by angiogenic mediators. Because of the highly angiogenic phenotype of renal cell carcinoma (RCC), we sought to assess the potential of CECs as a marker of RCC in patients with von Hippel-Lindau (VHL) disease and those with sporadic RCC. METHODS: We performed multicolour flow cytometry to enumerate CECs in patients with RCC, patients with VHL disease with and without RCC, and normal subjects. Two subsets of CECs were evaluated: mature CECs (mCECs) and circulating endothelial progenitors (CEPs). RESULTS: In patients with VHL disease and RCC and those with sporadic RCC (N = 10), CEPs and the CEP:mCEC ratio were higher than in normal subjects (N = 17) (median CEPs: 0.97 vs 0.19 cells mu l(-1), respectively, P<0.01; median CEP:mCEC:0.92 vs 0.58, respectively, P = 0.04). However, in patients with VHL without RCC, CECs were not increased. In paired pre- and post-nephrectomy RCC patient samples (N = 20), CEPs decreased after surgery (median difference 0.02 cells mu l(-1), -0.06 to 1.2; P = 0.05). CONCLUSION: Circulating endothelial progenitors were elevated in RCC, but not in patients with VHL without RCC. Circulating endothelial progenitor enumeration merits further investigation as a monitoring strategy for patients with VHL. British Journal of Cancer (2011) 105, 112-117. doi:10.1038/bjc.2011.186 www.bjcancer.com Published online 14 June 2011 (C) 2011 Cancer Research UK
引用
收藏
页码：112 / 117
页数：6
相关论文
共 24 条
[1]   Isolation of putative progenitor endothelial cells for angiogenesis [J].
Asahara, T ;
Murohara, T ;
Sullivan, A ;
Silver, M ;
vanderZee, R ;
Li, T ;
Witzenbichler, B ;
Schatteman, G ;
Isner, JM .
SCIENCE, 1997, 275 (5302) :964-967
[2]   VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells [J].
Asahara, T ;
Takahashi, T ;
Masuda, H ;
Kalka, C ;
Chen, DH ;
Iwaguro, H ;
Inai, Y ;
Silver, M ;
Isner, JM .
EMBO JOURNAL, 1999, 18 (14) :3964-3972
[3]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[4]   Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity [J].
Beaudry, P ;
Force, J ;
Naumov, GN ;
Wang, A ;
Baker, CH ;
Ryan, A ;
Soker, S ;
Johnson, BE ;
Folkman, J ;
Heymach, JV .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3514-3522
[5]  
Bertolini F, 2003, CANCER RES, V63, P4342
[6]   Biomarkers for monitoring antiangiogenic therapy [J].
Bhatt, Rupal S. ;
Seth, Pankaj ;
Sukhatme, Vikas P. .
CLINICAL CANCER RESEARCH, 2007, 13 (02) :777S-780S
[7]   Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab [J].
Calleri, Angelica ;
Bono, Anna ;
Bagnardi, Vincenzo ;
Quarna, Jessica ;
Mancuso, Patrizia ;
Rabascio, Cristina ;
Dellapasqua, Silvia ;
Campagnoli, Elisabetta ;
Shaked, Yuval ;
Goldhirsch, Aron ;
Colleoni, Marco ;
Bertolini, Francesco .
CLINICAL CANCER RESEARCH, 2009, 15 (24) :7652-7657
[8]   Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 [J].
Ceradini, DJ ;
Kulkarni, AR ;
Callaghan, MJ ;
Tepper, OM ;
Bastidas, N ;
Kleinman, ME ;
Capla, JM ;
Galiano, RD ;
Levine, JP ;
Gurtner, GC .
NATURE MEDICINE, 2004, 10 (08) :858-864
[9]   Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models [J].
Daenen, Laura G. ;
Shaked, Yuval ;
Man, Shan ;
Xu, Ping ;
Voest, Emile E. ;
Hoffman, Robert M. ;
Chaplin, David J. ;
Kerbel, Robert S. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (10) :2872-2881
[10]   Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells [J].
Farace, F. ;
Massard, C. ;
Borghi, E. ;
Bidart, J.-M. ;
Soria, J.-C. .
ANNALS OF ONCOLOGY, 2007, 18 (08) :1421-1422
123